Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

Rhea-AI Summary

Kiniksa Pharmaceuticals reported strong Q1 2025 financial results, with ARCALYST generating net product revenue of $137.8 million, marking a 75% year-over-year growth. The company raised its 2025 ARCALYST revenue guidance to $590-605 million from previous $560-580 million.

Key highlights:

• Over 3,150 prescribers have written ARCALYST prescriptions for recurrent pericarditis
• Average treatment duration increased to 30 months from 27 months in Q4 2024
• Total Q1 2025 revenue: $137.8 million
• Net income: $8.5 million, compared to $17.7 million loss in Q1 2024
• Cash position: $268.3 million with no debt

The company plans to initiate a Phase 2/3 trial for KPL-387 in mid-2025, with Phase 2 data expected in 2H 2026. KPL-387 aims to offer monthly subcutaneous dosing for recurrent pericarditis. Kiniksa expects to maintain positive annual cash flow and continues monitoring potential tariff implications on pharmaceuticals.

Positive

• Q1 2025 ARCALYST revenue hit $137.8M, up 75% year-over-year
• Increased 2025 revenue guidance to $590-605M from previous $560-580M
• Average treatment duration increased to 30 months from 27 months in Q4 2024
• Over 3,150 prescribers have written ARCALYST prescriptions
• Company achieved net income of $8.5M vs $17.7M loss in Q1 2024
• Strong cash position of $268.3M with zero debt
• Operating plan expected to remain cash flow positive

Negative

• Operating expenses increased to $124.5M from $96.4M year-over-year
• Collaboration expenses rose significantly to $43.8M from $20.8M
• Potential future tariff impact on drug substance imported from South Korea
• KPL-387 Phase 2 data not expected until second half of 2026

Insights

Financial Analyst

Kiniksa reports 75% revenue growth, turns profitable with $8.5M net income, raises 2025 guidance amid strong ARCALYST performance.

Kiniksa's Q1 2025 results demonstrate exceptional financial execution with ARCALYST generating $137.8 million in net product revenue, representing a 75% year-over-year growth. This strong performance has enabled management to raise full-year ARCALYST revenue guidance to $590-$605 million from the previous $560-$580 million range.

The company has reached a crucial financial inflection point, transitioning from a net loss of $17.7 million in Q1 2024 to a net income of $8.5 million in Q1 2025. This shift to profitability comes despite increased operating expenses ($124.5 million vs $96.4 million YoY), with $43.8 million attributed to collaboration expenses driven by ARCALYST's commercial success.

Kiniksa maintains a strong balance sheet with $268.3 million in cash, cash equivalents, and short-term investments with no debt. Management has reiterated expectations to remain cash flow positive on an annual basis, providing operational runway for continued pipeline development without additional capital needs.

The average duration of ARCALYST therapy increasing to approximately 30 months (from 27 months in Q4 2024) indicates strong patient retention and suggests robust recurring revenue streams. The company noted that Medicare Part D changes contributed to increasing active commercial patients, providing an additional growth driver.

Pharmaceutical Industry Expert

ARCALYST shows strong market adoption with 3,150+ prescribers and extending treatment duration while pipeline advances on schedule.

Kiniksa's ARCALYST continues to demonstrate strong market penetration with over 3,150 prescribers having written prescriptions for recurrent pericarditis since launch. The extension of average therapy duration to approximately 30 months (compared to 27 months in Q4 2024) suggests improving patient persistence, a critical metric for chronic therapies that indicates favorable real-world efficacy and tolerability.

The company's pipeline progression remains on track with KPL-387, a monoclonal antibody IL-1 receptor antagonist. Pharmacokinetic data from the Phase 1 study supports advancing to a Phase 2/3 clinical trial in recurrent pericarditis, scheduled to initiate in mid-2025. Kiniksa is positioning KPL-387 with a monthly subcutaneous dosing profile in a liquid formulation, which could potentially improve patient convenience. Data from the Phase 2 portion is expected in the second half of 2026.

Additionally, KPL-1161, an Fc-modified monoclonal antibody IL-1 receptor antagonist, is undergoing IND-enabling development activities with a target profile of quarterly subcutaneous dosing, potentially expanding treatment options with less frequent administration.

Kiniksa is addressing potential manufacturing risks by transferring drug substance manufacturing for ARCALYST from U.S.-based Regeneron to Samsung Biologics in South Korea. The company states any future impact from potential tariffs on pharmaceuticals imported into the United States would be immaterial, limited only to the cost of drug substance imported.

– ARCALYST^® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth –
– ARCALYST 2025 expected net product revenue increased to $590 - $605 million –
– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –
– Current operating plan expected to remain cash flow positive on an annual basis –
– Conference call and webcast scheduled for 8:30 am ET today –

LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported first quarter 2025 financial results and recent portfolio execution.

“Kiniksa continues to drive strong growth with ARCALYST. In the first quarter of 2025, our robust commercial execution resulted in a meaningful increase in active commercial patients, driven by increases to the prescriber base, longer average total duration of treatment, and changes to Medicare Part D. As a result of strong first quarter performance, we are increasing our expected 2025 ARCALYST net sales to between $590 and $605 million from our previous guidance of between $560 and $580 million,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. “Also, we are excited about the potential of KPL-387 to be an additional treatment option for patients by enabling dosing with a single monthly subcutaneous injection in a liquid formulation. We remain on track to initiate the KPL-387 Phase 2/3 recurrent pericarditis trial in the middle of this year.”

Portfolio Execution
ARCALYST (IL-1α and IL-1β cytokine trap)

• ARCALYST net product revenue was $137.8 million for the first quarter of 2025.
• Since launch, more than 3,150 prescribers have written ARCALYST prescriptions for recurrent pericarditis.
• As of the end of the first quarter of 2025, average total duration of ARCALYST therapy in recurrent pericarditis increased to approximately 30 months, compared to approximately 27 months as of the end of the fourth quarter of 2024.
  

KPL-387 (monoclonal antibody IL-1 receptor antagonist)

• Pharmacokinetic data from the single ascending dose portion of the Phase 1 study support the development plan for KPL-387; Kiniksa plans to initiate a Phase 2/3 clinical trial in mid-2025. The trial will evaluate KPL-387 in recurrent pericarditis, with a target profile of monthly subcutaneous (SC) dosing in a liquid formulation. The company expects data from the Phase 2 portion of the trial in the second half of 2026.
  

KPL-1161 (Fc-modified monoclonal antibody IL-1 receptor antagonist)

• Kiniksa is conducting Investigational New Drug (IND)-enabling development activities with a target profile of quarterly SC dosing.
  

Financial Results

• Total revenue for the first quarter of 2025 was $137.8 million, compared to $79.9 million for the first quarter of 2024.
  • Kiniksa did not record any license and collaboration revenue for the first quarter of 2025, compared to $1.0 million for the first quarter of 2024.
• Total operating expenses for the first quarter of 2025 were $124.5 million, compared to $96.4 million for the first quarter of 2024.
  • Total operating expenses for the first quarter of 2025 included $43.8 million in collaboration expenses, which are driven by ARCALYST collaboration profitability, compared to $20.8 million for the first quarter of 2024.
  • Total operating expenses for the first quarter of 2025, included $7.7 million in non-cash, share-based compensation expense, compared to $7.2 million for the first quarter of 2024.
• Net income for the first quarter of 2025 was $8.5 million, compared to a net loss of $17.7 million for the first quarter of 2024.
• As of March 31, 2025, Kiniksa had $268.3 million of cash, cash equivalents, and short-term investments and no debt.
  

Financial Guidance

• Kiniksa expects 2025 ARCALYST net product revenue of between $590 million and $605 million, compared to prior guidance of between $560 million and $580 million.
• Kiniksa expects its current operating plan to remain cash flow positive on an annual basis.
• Kiniksa continues to monitor potential implications of tariffs on pharmaceuticals imported into the United States.
  • ARCALYST is currently manufactured in the United States by Regeneron Pharmaceuticals. Kiniksa has been in the process of transferring drug substance manufacturing to Samsung Biologics in South Korea and believes any future impact to ARCALYST gross margin would be immaterial, limited only to the cost of drug substance imported into the United States.

Conference Call Information

• Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, April 29, 2025, to discuss first quarter 2025 financial results and recent portfolio execution.
• Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. To access the webcast, please visit the Investors and Media section of Kiniksa’s website. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.

About ARCALYST
ARCALYST is a weekly, subcutaneously injected recombinant dimeric fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling. ARCALYST was discovered by Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the U.S. Food and Drug Administration (FDA) for recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome, and deficiency of IL-1 receptor antagonist (DIRA). The FDA granted Breakthrough Therapy designation to ARCALYST for the treatment of recurrent pericarditis in 2019 and Orphan Drug exclusivity to ARCALYST in 2021 for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and pediatric patients 12 years and older. The European Commission granted Orphan Drug Designation to ARCALYST for the treatment of idiopathic pericarditis in 2021.

IMPORTANT SAFETY INFORMATION ABOUT ARCALYST

• ARCALYST may affect your immune system and can lower the ability of your immune system to fight infections. Serious infections, including life-threatening infections and death, have happened in patients taking ARCALYST. If you have any signs of an infection, call your doctor right away. Treatment with ARCALYST should be stopped if you get a serious infection. You should not begin treatment with ARCALYST if you have an infection or have infections that keep coming back (chronic infection).
• While taking ARCALYST, do not take other medicines that block interleukin-1, such as Kineret^® (anakinra), or medicines that block tumor necrosis factor, such as Enbrel^® (etanercept), Humira^® (adalimumab), or Remicade^® (infliximab), as this may increase your risk of getting a serious infection.
• Talk with your doctor about your vaccine history. Ask your doctor whether you should receive any vaccines before you begin treatment with ARCALYST.
• Medicines that affect the immune system may increase the risk of getting cancer.
• Stop taking ARCALYST and call your doctor or get emergency care right away if you have any symptoms of an allergic reaction.
• Your doctor will do blood tests to check for changes in your blood cholesterol and triglycerides.
• Common side effects include injection-site reactions (which may include pain, redness, swelling, itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the injection site), upper respiratory tract infections, joint and muscle aches, rash, ear infection, sore throat, and runny nose.
  

For more information about ARCALYST, talk to your doctor and see the Product Information.

About KPL-387
KPL-387 is an independently developed, investigational, fully human immunoglobulin G2 (IgG2) monoclonal antibody that binds human interleukin-1 receptor 1 (IL-1R1), inhibiting the signaling of the cytokines IL-1α and IL-1β. Kiniksa believes KPL-387 could expand the treatment options for recurrent pericarditis patients by enabling dosing with a single monthly SC injection in a liquid formulation.

About KPL-1161
KPL-1161 is an independently developed, investigational, Fc-modified IgG2 monoclonal antibody that binds IL-1R1, inhibiting the signaling of the cytokines IL-1α and IL-1β, with a target profile of quarterly SC dosing. Kiniksa is currently engaging in IND-enabling development activities for KPL-1161.

Forward-Looking Statements
This press release contains forward-looking statements. In some cases, you can identify forward looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding: our expectation that ARCALYST 2025 net product revenue will be between $590 million and $605 million; our plan to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025, with Phase 2 data expected in the second half of 2026, and that we remain on track to meeting such plan; our expectation that our current operating plan will remain cash flow positive on an annual basis; our target profile of monthly dosing via a single subcutaneous injection in a liquid formulation for KPL-387; the expected impact of tariff policy on our gross margins; our target profile of quarterly dosing for KPL-1161; our beliefs about the mechanisms of our assets and potential impact of their approach; and our belief that our portfolio of assets offers the potential for differentiation.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including without limitation, the following: delays or difficulty in enrollment of patients in, and activation or continuation of sites for, our clinical trials; delays or difficulty in completing our clinical trials as originally designed; potential for changes between final data and any preliminary, interim, top-line or other data from clinical trials; our inability to replicate results from our earlier clinical trials or studies; impact of additional data from us or other companies, including the potential for our data to produce negative, inconclusive or commercially uncompetitive results; potential undesirable side effects caused by our products and product candidates; our inability to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities; potential for applicable regulatory authorities to not accept our filings, delay or deny approval of any of our product candidates or require additional data or trials to support approval; our reliance on third parties as the sole source of supply of the drug substance and drug product used in our products and product candidates; raw material, important ancillary product and drug substance and/or drug product shortages; our reliance on third parties to conduct research, clinical trials, and/or certain regulatory activities for our product candidates; complications in coordinating requirements, regulations and guidelines of regulatory authorities across jurisdictions for our clinical trials; business development activities and their impact on our financial performance and strategy; changes in our operating plan, business development strategy or funding requirements; existing or new competition; and the impact of global economic policy, including any uncertainty in national and international markets.

These and other important factors discussed in our filings with the U.S. Securities and Exchange Commission, including under the caption “Risk Factors” contained therein, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. Except as required by law, we disclaim any intention or obligation to update or revise any forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

ARCALYST^® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts! ^®

Kiniksa Investor Contact
Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com

Kiniksa Media Contact
Tyler Gagnon
(781) 431-9100
tgagnon@kiniksa.com

KINIKSA PHARMACEUTICALS, LTD.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(Unaudited)
								Three Months Ended
								March 31,
								2025				2024
Revenue:
Product revenue, net								$	137,785			$	78,885
License and collaboration revenue									—				973
Total revenue									137,785				79,858
Operating expenses:
Cost of goods sold									17,868				10,583
Collaboration expenses									43,790				20,801
Research and development									19,325				26,334
Selling, general and administrative									43,530				38,682
Total operating expenses									124,513				96,400
Income (loss) from operations									13,272				(16,542	)
Other income									2,293				2,266
Income (loss) before income taxes									15,565				(14,276	)
Provision for income taxes									(7,026	)			(3,428	)
Net income (loss)								$	8,539			$	(17,704	)
Net income (loss) per share attributable to ordinary shareholders—basic								$	0.12			$	(0.25	)
Net income (loss) per share attributable to ordinary shareholders—diluted								$	0.11			$	(0.25	)
Weighted average ordinary shares outstanding—basic									72,647,121				70,633,023
Weighted average ordinary shares outstanding—diluted									76,145,617				70,633,023

KINIKSA PHARMACEUTICALS, LTD.
SELECTED CONSOLIDATED BALANCE SHEET DATA
(In thousands)
(Unaudited)
								As of
								March 31,				December 31,
									2025				2024
Cash, cash equivalents, and short-term investments								$	268,340			$	243,627
Working capital									258,640				231,178
Total assets									599,326				580,553
Accumulated deficit									(512,604	)			(521,143	)
Total shareholders' equity									457,489				438,436

FAQ

How much revenue did ARCALYST generate for Kiniksa (KNSA) in Q1 2025?

ARCALYST generated $137.8 million in net product revenue for Kiniksa (KNSA) in Q1 2025, representing a 75% year-over-year growth compared to Q1 2024.

What is Kiniksa's (KNSA) updated revenue guidance for ARCALYST in 2025?

Kiniksa raised its 2025 ARCALYST revenue guidance to $590-605 million, up from the previous guidance of $560-580 million, following strong Q1 2025 performance.

When will Kiniksa (KNSA) release Phase 2 data for KPL-387 in recurrent pericarditis?

Kiniksa expects to release Phase 2 data for KPL-387 in recurrent pericarditis during the second half of 2026, with the Phase 2/3 trial starting in mid-2025.

How many doctors have prescribed ARCALYST since its launch by Kiniksa (KNSA)?

More than 3,150 prescribers have written ARCALYST prescriptions for recurrent pericarditis since its launch.

What is the average treatment duration for ARCALYST patients as of Q1 2025?

The average total duration of ARCALYST therapy increased to approximately 30 months by the end of Q1 2025, up from 27 months in Q4 2024.

Is Kiniksa (KNSA) profitable in Q1 2025?

Yes, Kiniksa reported a net income of $8.5 million in Q1 2025, compared to a net loss of $17.7 million in Q1 2024, and expects to remain cash flow positive annually.